JP2015517470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517470A5 JP2015517470A5 JP2015510508A JP2015510508A JP2015517470A5 JP 2015517470 A5 JP2015517470 A5 JP 2015517470A5 JP 2015510508 A JP2015510508 A JP 2015510508A JP 2015510508 A JP2015510508 A JP 2015510508A JP 2015517470 A5 JP2015517470 A5 JP 2015517470A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- seq
- acid sequence
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642749P | 2012-05-04 | 2012-05-04 | |
| US61/642,749 | 2012-05-04 | ||
| US201361785559P | 2013-03-14 | 2013-03-14 | |
| US61/785,559 | 2013-03-14 | ||
| PCT/US2013/039744 WO2013166500A1 (en) | 2012-05-04 | 2013-05-06 | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018120054A Division JP6704954B2 (ja) | 2012-05-04 | 2018-06-25 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517470A JP2015517470A (ja) | 2015-06-22 |
| JP2015517470A5 true JP2015517470A5 (https=) | 2016-06-23 |
| JP6411329B2 JP6411329B2 (ja) | 2018-10-24 |
Family
ID=48428719
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510508A Active JP6411329B2 (ja) | 2012-05-04 | 2013-05-06 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
| JP2018120054A Active JP6704954B2 (ja) | 2012-05-04 | 2018-06-25 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
| JP2020084311A Pending JP2020127426A (ja) | 2012-05-04 | 2020-05-13 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
| JP2022086515A Withdrawn JP2022119907A (ja) | 2012-05-04 | 2022-05-27 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018120054A Active JP6704954B2 (ja) | 2012-05-04 | 2018-06-25 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
| JP2020084311A Pending JP2020127426A (ja) | 2012-05-04 | 2020-05-13 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
| JP2022086515A Withdrawn JP2022119907A (ja) | 2012-05-04 | 2022-05-27 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9441045B2 (https=) |
| EP (2) | EP2844674A1 (https=) |
| JP (4) | JP6411329B2 (https=) |
| AU (1) | AU2013256010B2 (https=) |
| CA (1) | CA2871751C (https=) |
| HK (1) | HK1207655A1 (https=) |
| WO (1) | WO2013166500A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2585004B2 (ja) | 1987-07-15 | 1997-02-26 | 太洋鋳機株式会社 | 連続式混練機における自動清掃装置 |
| AU2013256010B2 (en) * | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
| US20160237159A1 (en) * | 2013-10-11 | 2016-08-18 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for regulatory t-cell ablation |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JP6795505B2 (ja) * | 2014-10-06 | 2020-12-02 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法 |
| BR112017013176A2 (en) | 2014-12-19 | 2018-05-15 | Dana-Farber Cancer Institute Inc. | chimeric antigen receptors and methods for using them |
| EP3288977B1 (en) * | 2015-05-01 | 2021-11-17 | Dana-Farber Cancer Institute, Inc. | Methods of mediating cytokine expression with anti ccr4 antibodies |
| JP7126941B2 (ja) | 2015-12-22 | 2022-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ |
| TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| CA3037518A1 (en) * | 2016-09-21 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use |
| JP7269167B2 (ja) | 2016-10-14 | 2023-05-08 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | モジュラー四価二重特異性抗体プラットフォーム |
| KR20240011262A (ko) | 2017-02-21 | 2024-01-25 | 리제너론 파아마슈티컬스, 인크. | 폐암의 치료를 위한 항-pd-1 항체 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| RU2020118594A (ru) | 2017-11-06 | 2021-12-09 | Рапт Терапьютикс, Инк. | Противораковые агенты |
| CN108250290B (zh) | 2018-02-23 | 2024-03-12 | 上海捌加壹医药科技有限公司 | Ccr4的n端重组蛋白及其用途 |
| AU2019235900B2 (en) | 2018-03-14 | 2025-12-11 | Dana-Farber Cancer Institute, Inc. | Engineered cells, T cell immune modulating antibodies and methods for using the same |
| BR112021000391A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a ccr4 |
| WO2020113224A2 (en) | 2018-11-30 | 2020-06-04 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptor factories and methods of use thereof |
| AU2020290579B2 (en) | 2019-06-14 | 2026-02-12 | Dana-Farber Cancer Institute, Inc. | Antibodies against MUC1 and methods of use thereof |
| CN113388640B (zh) * | 2020-06-11 | 2022-12-20 | 百奥赛图(北京)医药科技股份有限公司 | Ccr4基因人源化的非人动物及其构建方法和应用 |
| WO2022117572A2 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | An ltbr agonist in combination therapy against cancer |
| WO2022208505A1 (en) * | 2021-04-01 | 2022-10-06 | 4C Biomed Limited | Enhanced anti-hvem antibodies and use thereof |
| WO2024163530A2 (en) * | 2023-02-01 | 2024-08-08 | Crown Bioscience Inc. | Novel anti-ccr4 antibodies and derivative products |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993004701A1 (en) | 1991-09-05 | 1993-03-18 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
| US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| WO1995022618A1 (en) | 1994-02-22 | 1995-08-24 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| US8962806B2 (en) * | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| AU2013256010B2 (en) * | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
| US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
-
2013
- 2013-05-06 AU AU2013256010A patent/AU2013256010B2/en active Active
- 2013-05-06 US US14/398,910 patent/US9441045B2/en active Active
- 2013-05-06 JP JP2015510508A patent/JP6411329B2/ja active Active
- 2013-05-06 EP EP13722266.7A patent/EP2844674A1/en not_active Ceased
- 2013-05-06 WO PCT/US2013/039744 patent/WO2013166500A1/en not_active Ceased
- 2013-05-06 EP EP18209618.0A patent/EP3511343A1/en active Pending
- 2013-05-06 CA CA2871751A patent/CA2871751C/en active Active
- 2013-05-06 HK HK15108293.0A patent/HK1207655A1/xx unknown
-
2015
- 2015-08-07 US US14/820,882 patent/US9587028B2/en active Active
-
2017
- 2017-01-27 US US15/418,510 patent/US20180094064A1/en not_active Abandoned
-
2018
- 2018-06-25 JP JP2018120054A patent/JP6704954B2/ja active Active
- 2018-12-17 US US16/222,342 patent/US20190276544A1/en not_active Abandoned
-
2020
- 2020-05-13 JP JP2020084311A patent/JP2020127426A/ja active Pending
-
2022
- 2022-05-27 JP JP2022086515A patent/JP2022119907A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517470A5 (https=) | ||
| JP2020127426A5 (https=) | ||
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| JP2015535691A5 (https=) | ||
| JP2022159548A5 (https=) | ||
| JP2020193210A5 (https=) | ||
| JP2017531427A5 (https=) | ||
| CN110291109B (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| JP2013502913A5 (https=) | ||
| ES2887299T3 (es) | Cadena J modificada | |
| JP2019513777A5 (https=) | ||
| JP2013227339A5 (https=) | ||
| JP2020103301A5 (https=) | ||
| JP2017537972A5 (https=) | ||
| JP2020525032A5 (https=) | ||
| JP2017506067A5 (https=) | ||
| JP2021508255A5 (https=) | ||
| JP2014076062A5 (https=) | ||
| US20240199750A1 (en) | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging | |
| JP2015502138A5 (https=) | ||
| JP2018502060A5 (https=) | ||
| JP2017522043A5 (https=) | ||
| JP2020515247A5 (https=) | ||
| JP2021512151A5 (https=) | ||
| JP2021510736A5 (https=) |